What is gemcitabine injection used for?
Pharmaceutical Product Monograph: Gemcitabine for Injection (200 mg, 1 g)
In the pharmaceutical industry, Gemcitabine is a parenteral, fluorine-substituted Antimetabolite and a Pyrimidine Analog. As a pharmacist and manufacturer, I view this molecule as the “DNA-Saboteur”—it is technically designed to mimic the natural building blocks of DNA, tricking the cancer cell into incorporating it, which then triggers a catastrophic “masked chain termination.”
At your WHO-GMP facility in Mumbai, Gemcitabine is a high-value SKU for Oncology and Specialty Care portfolios. It is the “gold standard” for difficult-to-treat solid tumors, particularly in the pancreas and lungs.
Therapeutic Profile: Primary Indications
Gemcitabine is a versatile chemotherapy agent used either as monotherapy or in “platinum-doublet” combinations (e.g., Gemcitabine + Cisplatin).
| Indication | Clinical Context | Technical Rationale |
| Pancreatic Cancer | First-Line Therapy | Gold Standard: The primary drug for locally advanced or metastatic adenocarcinoma of the pancreas. |
| Non-Small Cell Lung (NSCLC) | Combination Therapy | Used with Cisplatin for patients with inoperable, locally advanced, or metastatic NSCLC. |
| Breast Cancer | Metastatic | Combined with Paclitaxel for patients whose cancer has relapsed after anthracycline therapy. |
| Ovarian Cancer | Advanced / Relapsed | Combined with Carbapenem/Cisplatin for advanced epithelial ovarian cancer that has recurred. |
| Bladder Cancer | Urothelial Carcinoma | An effective alternative or addition to standard regimens for advanced bladder cancer. |
Mechanism: The “Masked Chain Termination”
Gemcitabine is a pro-drug that requires “activation” inside the cell to destroy cancer DNA:
Phosphorylation: Once inside the cell, it is converted by deoxycytidine kinase into its active forms: Gemcitabine Diphosphate (dFdCDP) and Triphosphate (dFdCTP).
Ribonucleotide Reductase Inhibition: The diphosphate form inhibits the enzyme that produces the “normal” DNA building blocks, effectively starving the cell of its natural resources.
DNA Insertion: The triphosphate form competes with natural “cytidine” to be built into the DNA strand.
The “Masked” Lock: Once Gemcitabine is added, only one additional natural nucleotide can be attached. After that, the DNA strand is permanently “locked” and cannot grow further. This “masked” termination prevents the cell’s repair enzymes from finding and fixing the error, leading to Apoptosis (cell death).
The Pharmacist’s “Technical Warning”
Infusion Time Matters: As a pharmacist, I must emphasize that Gemcitabine must be infused over exactly 30 minutes. Technically, extending the infusion time beyond 60 minutes significantly increases toxicity (severe drop in blood counts and flu-like symptoms) without increasing efficacy.
Myelosuppression: It causes a dose-dependent drop in platelets (thrombocytopenia) and white blood cells. Blood counts must be checked before every single dose.
Pulmonary Toxicity: In rare cases, it can cause severe lung inflammation (interstitial pneumonitis). Any new-onset shortness of breath must be reported immediately.
The “Radiosensitizer” Effect: Gemcitabine makes cells extremely sensitive to radiation. It should technically not be used concurrently with high-dose radiation therapy unless specifically indicated.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Lyophilized Cake” USP: On your digital marketplace, highlight your High-Purity Lyophilized Powder. Gemcitabine is most stable as a freeze-dried cake. Your vacuum-drying process ensures a robust 24-month shelf life.
The “RTU” Liquid Advantage: If your facility produces the Ready-to-Use (RTU) liquid form, market this as a “Safety-First” SKU. It eliminates the need for reconstitution, reducing the risk of “needle-stick” injuries and hazardous aerosol exposure for oncology nurses.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Gemcitabine 200 mg and 1 g vials to support your registration in international B2B oncology tenders.